Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11064343 | 0.93 | UGT2B7 (0.59) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL13558378 | 0.89 | UGT2B7 (0.52) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL30033673 | 0.85 | UGT2B7 (0.68) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL600527 | 0.85 | UGT2B7 (0.68) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL3169520 | 0.84 | UGT2B7 (0.48) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL445001 | 0.81 | UGT2B7 (1.00) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL8474125 | 0.81 | UGT2B7 (0.63) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL15352903 | 0.81 | UGT2B7 (0.63) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL110360 | 0.81 | UGT2B7 (1.00) | UGT2B7MEN1KMT2AATMSLC6A2 | |
| SCHEMBL7649891 | 0.81 | UGT2B7 (0.63) | UGT2B7MEN1KMT2AATMSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754221-B2 | Optically active cyclic alcohol compound and method for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-17 | — | — | US | claimed |
| US-20130237708-A1 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-12 | — | — | US | claimed |
| EP-1944291-B1 | Optically active cyclic alcohol compound and method for producing same | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-06-13 | — | — | EP | claimed |
| US-20100152451-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-17 | — | — | US | claimed |
| EP-1944291-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PRODUCING SAME | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-16 | — | — | EP | claimed |
| CN-1361759-A | 6-hydroxy-2-naphthyl carbinol and process for producing the same | MITSUBISHI CHEM CORP (JP) | 2002-07-31 | — | — | CN | claimed |
| US-5527899-A | STABILIZATION THE SINGLE-STRAND OLIGONUCLEOTIDE TO EXONUCLEASE DEGRADATION | GILEAD SCIENCES, INC. (US) | 1996-06-18 | — | — | US | claimed |
| US-5399676-A | DNA sequence identification | GILEAD SCIENCES (US) | 1995-03-21 | — | — | US | claimed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | claimed |
| US-20230331689-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | LT MATERIALS CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
| US-20210317490-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A., (ES) | 2021-10-14 | — | — | US | disclosed |
| US-20210139521-A1 | DIARYL TREHALOSE COMPOUNDS AND USES THEREOF | THE UNIV OF MONTANA (US) | 2021-05-13 | — | — | US | disclosed |
| CN-108884212-B | Maleimide resin, curable resin composition and cured product thereof | 日本化药株式会社 | 2020-12-29 | — | — | CN | disclosed |
| EP-3640236-A1 | A METHOD OF PRODUCING INGENOL-3-ANGELATE | LEO LABORATORIES LIMITED (IE) | 2020-04-22 | — | — | EP | disclosed |
| EP-0311387-A2 | Aromatic amine resins, their production process and thermosetting resin compositions making use of the same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-04-12 | — | — | EP | disclosed |
| US-4518609-A | ANTITUMOR, SKIN DISORDERS | SRI INTERNATIONAL (US) | 1985-05-21 | — | — | US | disclosed |
| US-4456618-A | ANTITUMOR AGENTS, TREATMENT OF SKIN DISORDERS | SRI INTERNATIONAL (US) | 1984-06-26 | — | — | US | disclosed |
| US-4436804-A | Light-sensitive polymeric diazonium condensates and reproduction compositions and materials therewith | AMERICAN HOECHST CORPORATION (US) | 1984-03-13 | — | — | US | disclosed |
| US-4101274-A | DISPERSE DYES, POLYESTERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-07-18 | — | — | US | disclosed |
| US-4025553-A | Production of o-hydroxybenzyl alcohols | SHIONOGI & CO., LTD. (JA) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317490-A1 | ANTICANCER COMPOUNDS | SLC75A1, SLC15A1, LCT | UGT2B7 1401/4885MEN1 1707/4885KMT2A 944/4885 |
| US-20100152451-A1 | OPTICALLY ACTIVE CYCLIC ALCOHOL COMPOUND AND METHOD FOR PREPARING THE SAME | ADH1C, ADH1A, ADH5 | UGT2B7 216/4885MEN1 2662/4885KMT2A 1394/4885 |
| US-20130237708-A1 | Optically Active Cyclic Alcohol Compound And Method For Preparing The Same | ADH1C, ADH1A, ADH5 | UGT2B7 216/4885MEN1 2662/4885KMT2A 1394/4885 |
| US-20230331689-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, CYP1A1 | UGT2B7 184/4885MEN1 225/4885KMT2A 574/4885 |
| US-20210139521-A1 | DIARYL TREHALOSE COMPOUNDS AND USES THEREOF | TREH, STT3B, DDOST | UGT2B7 1975/4885MEN1 3708/4885KMT2A 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.